Skip to content
OpenCapital
Get started

Aclaris Therapeutics ACRS Single Reportable — Research And Development Project Spend

Similar metrics at other companies

Merit Medical Systems logo
MMSISingle Reportable — Research And Development Expense
$22.61M+0.6%
Celldex Therapeutics logo
CLDXSingle Reportable — Research And Development Expense
$73M+38.7%
908 Devices logo
MASSSingle Reportable — Research And Development Expense
$3.47M-9.3%
Axcelis Technologies logo
ACLSSingle Reportable — Research And Development Expense
$28.52M+5.1%
Iovance Biotherapeutics, Inc. logo
IOVASingle Reportable — Research And Development Expense
$57.37M-13.1%
Capricor Therapeutics logo
CAPRSingle Reportable — Research And Development Expense
$27.38M+44.7%

Other financials

Income statement

See full
Revenue$2.0M+37.2%
Gross profit$1.6M+68.7%
Operating income-$22.2M-22.7%
Net income-$19.8M-31.4%
EPS (diluted)-$0.15-25.0%

Balance sheet

See full
Cash & equivalents$28.7M-5.6%
Total debt$2.0M-20.1%
Total equity$143.6M-0.3%
Total assets$198.7M+0.3%

Cash flow

See full
Operating cash flow-$18.1M-39.0%
CapEx$13.0K-69.8%
Free cash flow-$18.2M-38.6%

Valuation

See full
Market cap$685.75M+337%
Enterprise value$659.07M+410%
P/S82×+73.1×

Profitability

See full
Gross margin76.3%-9.7pp
Operating margin-961.9%+259pp
Net margin-832.6%+132pp
FCF margin-624.9%—

Returns & leverage

See full
Return on equity-48.4%-15.4pp
Debt / equity0×0.0×
Current ratio4×-1.0×

Where this comes from

Reported directly by Aclaris Therapeutics in its filing.

Tagged under the XBRL concept acrs:ResearchAndDevelopmentProjectSpend.

The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aclaris Therapeutics's single reportable — research and development project spend.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aclaris Therapeutics's single reportable — research and development project spend?
Aclaris Therapeutics (ACRS) reported single reportable — research and development project spend of $10.48M in Q1 2026.
How has Aclaris Therapeutics's single reportable — research and development project spend changed year-over-year?
Aclaris Therapeutics's single reportable — research and development project spend increased by 46.4% year-over-year, from $7.16M to $10.48M.
What does single reportable — research and development project spend mean?
Reflects the direct capital or operational expenditure allocated specifically to ongoing research and development projects within the segment. It highlights the company's commitment to innovation and the advancement of its product pipeline. This metric is a key indicator of future growth potential and strategic investment in new therapeutic candidates.